Results 81 to 90 of about 24,793 (292)

New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. [PDF]

open access: yesPLoS ONE, 2013
Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse ...
Nelly Mezzaroba   +20 more
doaj   +1 more source

Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes

open access: yesAmerican Journal of Hematology, Volume 100, Issue 8, Page 1397-1407, August 2025.
Mixed autoimmune hemolytic anemia (AIHA) is a rare condition characterized by the presence of both warm and cold autoantibodies, often leading to severe, treatment‐resistant hemolysis. In this systematic review of 81 patients across 35 studies, the median age was 45 years with a notable female predominance.
Jeremy W. Jacobs   +12 more
wiley   +1 more source

α-Diaminobutyric acid-linked hairpin polyamides [PDF]

open access: yes, 2007
A hairpin polyamide-chlorambucil conjugate linked by α-diaminobutyric acid (α-DABA) has been shown to have interesting biological properties in cellular and small animal models.
Dervan, Peter B.   +2 more
core   +3 more sources

Changing therapeutic landscape - The last decade [PDF]

open access: yes, 2011
Undoubtedly the most important event in the previous decade in lymphoma treatment was the establishment of immunotherapy as a prime modality. Addition of rituximab improves survival in almost every group of patients with CD20+ tumors. This has led to the
Aurer, Igor
core   +1 more source

Physical Activity, Symptoms, Quality of Life and Exercise Program Preferences in People With Chronic Lymphocytic Leukaemia

open access: yeseJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Background Chronic lymphocytic leukaemia (CLL) has a heterogeneous lifelong course. While some patients never require treatment, most experience intermittent periods of active monitoring with other time points in active treatment. Most patients experience significant symptoms which negatively impact their quality of life (QoL).
Ellie E. Miles   +11 more
wiley   +1 more source

Primary identification of compounds targeting hepatitis B virus capsid formation from the FDA approved drugs

open access: yesDi-san junyi daxue xuebao, 2019
Objective To identify the candidates targeting capsid formation of HBV by screening a FDA approved drug library. Methods SRluc-HBc6 cells, which indicates the formation of HBc dimers by the split luciferase complementation (SLC), were used as the 1st ...
YUAN Yi   +4 more
doaj   +1 more source

Pulmonary Blastoma: A Case Report and Review of the Literature

open access: yesClinical Case Reports, Volume 13, Issue 7, July 2025.
ABSTRACT This report aimed to underscore the significance of pulmonary blastoma, a rare entity with limited literature, by contributing insights into its clinical features, diagnostic approaches, and treatment modalities. Additionally, it emphasizes the critical role of a multidisciplinary approach in the effective management of this complex and ...
Haseeb Ahsin   +4 more
wiley   +1 more source

The effects of splenic irradiation on lymphocyte subpopulations in chronic B-lymphocytic leukemia [PDF]

open access: yes, 1988
We describe the effect of splenic irradiation (SI) (0,5–1 Gy weekly) on lymphocyte subpopulations for 7 patients with progressive B chronic B-lymphocytic leukemia (B-CLL).
Aabo   +24 more
core   +3 more sources

Combined Application of CAR-T Cells and Chlorambucil for CLL Treatment: Insights from Nonlinear Dynamical Systems and Model-Based Design for Dose Finding

open access: yesHemato
Background: This work presents a mechanistic nonlinear model, formulated as a system of first-order Ordinary Differential Equations, to investigate the dynamics of Chronic Lymphocytic Leukemia (CLL) under combined chemoimmunotherapy using CAR-T cells and
Paul A. Valle   +4 more
doaj   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

open access: yes, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha   +161 more
core   +2 more sources

Home - About - Disclaimer - Privacy